Ocular Therapeutix, Inc. (OCUL) is a clinical-stage biopharmaceutical company focused on ophthalmic therapeutics, with a halal core business but financial screening challenges due to interest income exceeding thresholds. The company demonstrates strong debt management and no non-permissible business activities, but the 7.87% interest income ratio leads to non-compliance across major Shariah standards and indices. Purification is required for any dividends, and while trends show improvement, inclusion in Shariah indices remains absent. Investors may consider monitoring for further financial purification.